Form 4: Arcutis CEO Sells Shares for Tax Obligations

Arcutis Biotherapeutics CEO Todd Watanabe sold 11,547 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported the sale of 11,547 shares of common stock.
• The transaction occurred on August 4, 2025, at a weighted average sale price of $14.3266 per share.
• The shares were sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• Individual sale prices ranged from $13.965 to $14.675 per share.
• Following this transaction, Watanabe directly beneficially owns 901,569 shares of common stock.
• Watanabe also indirectly beneficially owns 25,410 shares through The John Franklin Watanabe Trust, 25,410 shares through The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares through Watanabe Ventures, LLC, and 124,956 shares through The Watanabe 2016 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported sale is a non-discretionary transaction to cover tax obligations related to RSU vesting, which is a routine event for executives and does not indicate a change in management's outlook on the company.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries when equity compensation vests. It does not reflect broader industry trends or competitive positioning.

Related Party Transactions

• Todd Watanabe disclaims beneficial ownership of shares held indirectly through The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, Watanabe Ventures, LLC, and The Watanabe 2016 Irrevocable Trust, except to the extent of his pecuniary interest.

Stakeholder Impact

• The impact on shareholders is minimal as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in company fundamentals or management's confidence.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by an insider to cover tax obligations from RSU vesting. This type of transaction does not provide new fundamental information about the company's performance, strategy, or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should hold their position and await more substantive financial or operational updates.

Keywords

Arcutis Biotherapeutics, ARQT, Todd Watanabe, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding